State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510000, China.
Comput Math Methods Med. 2021 Nov 25;2021:1175379. doi: 10.1155/2021/1175379. eCollection 2021.
To provide direction for clinical application and pharmaceutical exploitation, the activity of sulbactam compounds and PIP/TAZ 8 : 1 against clinical isolates of Gram-negative bacteria (GNB, = 976) was evaluated according to Clinical and Laboratory Standards Institute (CLSI) 2019. By minimal inhibitory concentrations (MICs), the resistance rate of all GNB to AMP/SBT 2 : 1 (56.9-100%) was significantly higher than other drugs, except the resistance rate of (, = 204) to piperacillin/tazobactam (PIP/TAZ 8 : 1, 78.4%) which was close to it (76.5%). Additionally, the resistance rate of to other compounds except AMP/SBT 2 : 1 differed greatly, but that of (, = 205) varied rarely. In addition, (, = 204) and demonstrated low and high resistance rates, respectively. Compared with cefoperazone/sulbactam (CPZ/SBT 2 : 1), PIP/TAZ 8 : 1 had advantage in anti- (RR = 0.5and OR = 2.17) and anti- activity (RR = 0.88and OR = 1.27), while its activity against (: = 194, RR = 0.91, and OR = 1.12), (RR = 1.31 and OR = 0.41), and other Enterobacteriaceae (other : = 169, RR = 1.40, and OR = 0.62) was not better than CPZ/SBT 2 : 1. Although it had advantage against (RR = 0.60 and OR = 1.78), (RR = 0.67 and OR = 1.63), and (RR = 0.70 and OR = 2.05), the inhibition effect of piperacillin/sulbactam (PIP/SBT 2 : 1) against (RR = 0.94 and OR = 1.12) and other was just similar with CPZ/SBT 2 : 1 (RR = 0.93 and OR = 1.10). Furthermore, the anti- (RR = 0.70 and OR = 1.50), anti- (RR = 0.89 and OR = 1.24), and anti- (RR = 0.74 and OR = 1.46) activities of ceftazidime/sulbactam (CAZ/SBT 1 : 1) had a weak advantage, while its activity against (RR = 0.94 and OR = 1.15) and other (RR = 0.79 and OR = 1.36) was just close to CPZ/SBT 2 : 1. Moreover, the inhibitory effect of PIP/SBT 1 : 1 against all tested clinical species was more active than CPZ/SBT 2 : 1, while that of CAZ/SBT 2 : 1 against all species of bacteria analyzed was weaker than the controls.
为了为临床应用和药物开发提供指导，根据临床和实验室标准协会（CLSI）2019 年的标准，评估了舒巴坦化合物和 PIP/TAZ 8:1 对临床分离的革兰氏阴性菌（GNB，=976）的活性。通过最小抑菌浓度（MICs），所有 GNB 对 AMP/SBT 2:1（56.9-100%）的耐药率明显高于其他药物，除了（=204）对哌拉西林/他唑巴坦（PIP/TAZ 8:1，78.4%）的耐药率接近（76.5%）。此外，除了 AMP/SBT 2:1 外，对其他化合物的耐药率差异很大，但（=205）的耐药率变化不大。此外，（=204）和表现出低和高耐药率，分别。与头孢哌酮/舒巴坦（CPZ/SBT 2:1）相比，PIP/TAZ 8:1 在抗（RR=0.5 和 OR=2.17）和抗（RR=0.88 和 OR=1.27）活性方面具有优势，而其对（：=194，RR=0.91，和 OR=1.12）、（RR=1.31 和 OR=0.41）和其他肠杆菌科（其他：=169，RR=1.40，和 OR=0.62）的活性并不优于 CPZ/SBT 2:1。尽管它对（RR=0.60 和 OR=1.78）、（RR=0.67 和 OR=1.63）和（RR=0.70 和 OR=2.05）具有优势，但哌拉西林/舒巴坦（PIP/SBT 2:1）对（RR=0.94 和 OR=1.12）和其他的抑制作用与 CPZ/SBT 2:1 相似（RR=0.93 和 OR=1.10）。此外，头孢他啶/舒巴坦（CAZ/SBT 1:1）的抗（RR=0.70 和 OR=1.50）、抗（RR=0.89 和 OR=1.24）和抗（RR=0.74 和 OR=1.46）活性具有微弱优势，而其对（RR=0.94 和 OR=1.15）和其他（RR=0.79 和 OR=1.36）的活性与 CPZ/SBT 2:1 相当。此外，PIP/SBT 1:1 对所有测试的临床菌株的抑制作用比 CPZ/SBT 2:1 更活跃，而 CAZ/SBT 2:1 对所有分析的细菌菌株的抑制作用比对照弱。
